Hypochlorite-modified high-density lipoprotein acts as a sink for myeloperoxidase in vitro

Cardiovascular Research

Volumn 79, Issue 1, 2008, Pages 187-194

  Marsche, Gunther ^a   Furtmüller, Paul G ^b   Obinger, Christian ^b   Sattler, Wolfgang ^a   Malle, Ernst ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

Author keywords

ApoA I; Hypochlorous acid; Inflammation; MPO hydrogen peroxide halide system; Neutrophils

Indexed keywords

HIGH DENSITY LIPOPROTEIN; HYPOCHLORITE; HYPOCHLOROUS ACID; IODINE 125; MYELOPEROXIDASE; TOSYLCHLORAMIDE SODIUM;

ARTICLE; BINDING AFFINITY; CARDIOVASCULAR RISK; CELL ADHESION; CHRONIC INFLAMMATION; ENDOTHELIUM CELL; ENZYME INHIBITION; ENZYME METABOLISM; ENZYME MODIFICATION; HUMAN; HUMAN CELL; IN VITRO STUDY; ISOTOPE LABELING; MACROPHAGE; PHAGOCYTOSIS; PRIORITY JOURNAL;

CELLS, CULTURED; CHLORAMINES; ENDOTHELIUM, VASCULAR; HUMANS; HYDROGEN PEROXIDE; HYPOCHLOROUS ACID; LIPOPROTEINS, HDL; PEROXIDASE; UMBILICAL VEINS;

EID: 45849125708     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvn051     Document Type: Article

References (51)

1. Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004;84:1381-1478.
2. Klebanoff SJ. Myeloperoxidase: friend and foe. J Leukoc Biol 2005;77:598-625.
3. Winterbourn CC. Comparative reactivities of various biological compounds with myeloperoxidase-hydrogen peroxide-chloride, and similarity of the oxidant to hypochlorite. Biochim Biophys Acta 1985;840:204-210.
4. van den Berg JJ, Winterbourn CC, Kuypers FA. Hypochlorous acidmediated modification of cholesterol and phospholipid: analysis of reaction products by gas chromatography-mass spectrometry. J Lipid Res 1993;34:2005- 2012.
5. Prütz WA. Hypochlorous acid interactions with thiols, nucleotides, DNA, and other biological substrates. Arch Biochem Biophys 1996;332:110-120.
6. Hawkins CL, Pattison DI, Davies MJ. Hypochlorite-induced oxidation of amino acids, peptides and proteins. Amino Acids 2003;25:259-274.
7. Malle E, Marsche G, Arnhold J, Davies MR. Modification of low-density lipoprotein by myeloperoxidase-derived oxidants and reagent hypochlorous acid. Biochim Biophys Acta 2006;1761:392-415.
8. Malle E, Marsche G, Panzenboeck U, Sattler W. Myeloperoxidase-mediated oxidation of high-density lipoproteins: fingerprints of newly recognized potential proatherogenic lipoproteins. Arch Biochem Biophys 2006;445:245-255.
9. Daugherty A, Dunn JL, Rateri DL, Heinecke JW. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 1994;94:437-444.
10. 2/halide system in human atherosclerotic lesions: colocalization of myeloperoxidase and hypochlorite-modified proteins. Eur J Biochem 2000;267:4495-4503.
11. Sugiyama S, Okada Y, Sukhova GK, Virmani R, Heinecke JW, Libby P. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol 2001;158:879-891.
12. Malle E, Wäg G, Thiery J, Sattler W, Gröne HJ. Hypochlorite-modified (lipo)proteins are present in rabbit lesions in response to dietary cholesterol. Biochem Biophys Res Commun 2001;289:894- 900.
13. Bergt C, Pennathur S, Fu X, Byun J, O'Brien K, McDonald TO et al. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc Natl Acad Sci USA 2004;101:13032-13037.
14. Hazell LJ, Arnold L, Flowers D, Waeg G, Malle E, Stocker R. Presence of hypochlorite-modified proteins in human atherosclerotic lesions. J Clin Invest 1996;97:1535-1544.
15. Nicholls SJ, Zheng L, Hazen SL. Formation of dysfunctional high-density lipoprotein by myeloperoxidase. Trends Cardiovasc Med 2005;15:212-219.
16. Bergt C, Reicher H, Malle E, Sattler W. Hypochlorite modification of high density lipoprotein: effects on cholesterol efflux from J774 macrophages. FEBS Lett 1999;452:295-300.
17. Zheng L, Settle M, Brubaker G, Schmitt D, Hazen SL, Smith JD et al. Localization of nitration and chlorination sites on apolipoprotein A-I catalyzed by myeloperoxidase in human atheroma and associated oxidative impairment in ABCA1-dependent cholesterol efflux from macrophages. J Biol Chem 2005;280:38-47.
18. Peng DQ, Wu Z, Brubaker G, Zheng L, Settle M, Gross E et al. Tyrosine modification is not required for myeloperoxidase-induced loss of apolipoprotein A-I functional activities. J Biol Chem 2005;280:33775-33784.
19. Shao B, Bergt C, Fu X, Green P, Voss JC, Oda MN et al. Tyrosine 192 in apolipoprotein A-I is the major site of nitration and chlorination by myeloperoxidase, but only chlorination markedly impairs ABCA1-dependent cholesterol transport. J Biol Chem 2005;280:5983-5993.
20. Panzenboeck U, Raitmayer S, Reicher H, Lindner H, Glatter O, Malle E et al. Effects of reagent and enzymatically generated hypochlorite on physicochemical and metabolic properties of high density lipoproteins. J Biol Chem 1997;272:29711-29720.
21. Zheng L, Nukuna B, Brennan ML, Sun M, Goormastic M, Settle M et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 2004;114:529-541.
22. Marsche G, Hammer A, Oskolkova O, Kozarsky KF, Sattler W, Malle E. Hypochlorite-modified high density lipoprotein, a high affinity ligand to scavenger receptor class B, type I, impairs high density lipoprotein-dependent selective lipid uptake and reverse cholesterol transport. J Biol Chem 2002;277:32172-32179.
23. Malle E, Ibovnik A, Steinmetz A, Kostner GM, Sattler W. Identification of glycoprotein IIb as the lipoprotein(a)-binding protein on platelets. Lipoprotein(a) binding is independent of an arginyl-glycyl-aspartate tripeptide located in apolipoprotein(a). Arterioscler Thromb 1994;14:345-352.
24. Marsche G, Levak-Frank S, Quehenberger O, Heller R, Sattler W, Malle E. Identification of the human analog of SR-BI and LOX-1 as receptors for hypochlorite-modified high density lipoprotein on human umbilical venous endothelial cells. FASEB J 2001;15:1095-1097.
25. Malle E, Ibovnik A, Leis HJ, Kostner GM, Verhallen PF, Sattler W. Lysine modification of LDL or lipoprotein(a) by 4-hydroxynonenal or malondialdehyde decreases platelet serotonin secretion without affecting platelet aggregability and eicosanoid formation. Arterioscler Thromb Vasc Biol 1995;15:377-384.
26. Furtmüller PG, Zederbauer M, Jantschko W, Helm J, Bogner M, Jakopitsch C et al. Active site structure and catalytic mechanisms of human peroxidases. Arch Biochem Biophys 2006;445:199-213.
27. Furtmüller PG, Jantschko W, Regelsberger G, Jakopitsch C, Arnhold J, Obinger C. Reaction of lactoperoxidase compound I with halides and thiocyanate. Biochemistry 2002;41:11895-11900.
28. Marsche G, Semlitsch M, Hammer A, Frank S, Weigle B, Demling N et al. Hypochlorite-modified albumin colocalizes with RAGE in the artery wall and promotes MCP-1 expression via the RAGE-Erk1/2 MAP-kinase pathway. FASEB J 2007;21:1145-1152.
29. Nuszkowski A, Gräbner R, Marsche G, Unbehaun A, Malle E, Heller R. Hypochlorite-modified low density lipoprotein inhibits nitric oxide synthesis in endothelial cells via an intracellular dislocalization of endothelial nitric-oxide synthase. J Biol Chem 2001;276:14212-14221.
30. Artl A, Marsche G, Lestavel S, Sattler W, Malle E. Role of serum amyloid A during metabolism of acute-phase HDL by macrophages. Arterioscler Thromb Vasc Biol 2000;20:763-772.
31. Tiruppathi C, Naqvi T, Wu Y, Vogel SM, Minshall RD, Malik AB. Albumin mediates the transcytosis of myeloperoxidase by means of caveolae in endothelial cells. Proc Natl Acad Sci USA 2004;101:7699-7704.
32. Malle E, Furtmüller PG, Sattler W, Obinger C. Myeloperoxidase: a target for new drug development? Br J Pharmacol 2007;152:838-854.
33. Baldus S, Eiserich JP, Mani A, Castro L, Figueroa M, Chumley P et al. Endothelial transcytosis of myeloperoxidase confers specificity to vascular ECM proteins as targets of tyrosine nitration. J Clin Invest 2001;108:1759-1770.
34. Thukkani AK, McHowat J, Hsu FF, Brennan ML, Hazen SL, Ford DA. Identification of alpha-chloro fatty aldehydes and unsaturated lysophosphatidylcholine molecular species in human atherosclerotic lesions. Circulation 2003;108:3128-3133.
35. Hirano K, Yamashita S, Nakagawa Y, Ohya T, Matsuura F, Tsukamoto K et al. Expression of human scavenger receptor class B type I in cultured human monocyte-derived macrophages and atherosclerotic lesions. Circ Res 1999;85:108-116.
36. Pussinen PJ, Metso J, Keva R, Hirschmugl B, Sattler W, Jauhiainen M et al. Plasma phospholipid transfer protein-mediated reactions are impaired by hypochlorite modification of high density lipoprotein. Int J Biochem Cell Biol 2003;35:192-202.
37. Wu Z, Wagner MA, Zheng L, Parks JS, Shy JM, Smith JD et al. The refined structure of nascent HDL reveals a key functional domain for particle maturation and dysfunction. Nat Struct Mol Biol 2007;14:861-868.
38. Bergt C, Oettl K, Keller W, Andreae F, Leis HJ, Malle E et al. Reagent or myeloperoxidase-generated hypochlorite affects discrete regions in lipid-free and lipid-associated human apolipoprotein A-I. Biochem J 2000;346:345-354.
39. Opper C, Schüssler G, Sattler W, Malle E. Effects of hypochlorite-modified low density lipoproteins and high density lipoproteins on platelet function. Platelets 1998;9:339-341.
40. 2+-ATPase activity of human platelets. Cell Calcium 1999;26:281-287.
41. Tatsumi T, Fliss H. Hypochlorous acid and chloramines increase endothelial permeability: possible involvement of cellular zinc. Am J Physiol 1994;267:H1597-H1607.
42. Mathy-Hartert M, Deby-Dupont G, Deby C, Jadoul L, Vandenberghe A, Lamy M. Cytotoxicity towards human endothelial cells, induced by neutrophil myeloperoxidase: protection by ceftazidime. Mediators Inflamm 1995;4:437-443.
43. Zhang C, Patel R, Eiserich JP, Zhou F, Kelpke S, Ma W et al. Endothelial dysfunction is induced by proinflammatory oxidant hypochlorous acid. Am J Physiol Heart Circ Physiol 2001;281:H1469-H1475.
44. Lefkowitz SS, Gelderman MP, Lefkowitz DL, Moguilevsky N, Bollen A. Phagocytosis and intracellular killing of Candida albicans by macrophages exposed to myeloperoxidase. J Infect Dis 1996;173:1202-1207.
45. Lau D, Mollnau H, Eiserich JP, Freeman BA, Daiber A, Gehling UM et al. Myeloperoxidase mediates neutrophil activation by association with CD11b/CD18 integrins. Proc Natl Acad Sci USA 2005;102:431-436.
46. Lefkowitz DL, Mills K, Morgan D, Lefkowitz SS. Macrophage activation and immunomodulation by myeloperoxidase. Proc Soc Exp Biol Med 1992;199:204-210.
47. Podrez EA, Abu-Soud HM, Hazen SL. Myeloperoxidase-generated oxidants and atherosclerosis. Free Radic Biol Med 2000;28:1717-1725.
48. Gröne HJ, Gröne EF, Malle E. Immunohistochemical detection of hypochlorite-modified proteins in glomeruli of human membranous glomerulonephritis. Lab Invest 2002;82:5-14.
49. Davies JM, Horwitz DA, Davies KJ. Potential roles of hypochlorous acid and N-chloroamines in collagen breakdown by phagocytic cells in synovitis. Free Radic Biol Med 1993;15:637-643.
50. Van Der Vliet A, Nguyen MN, Shigenaga MK, Eiserich JP, Marelich GP, Cross CE. Myeloperoxidase and protein oxidation in cystic fibrosis. Am J Physiol Lung Cell Mol Physiol 2000;279:L537-L546.
51. Aldridge RE, Chan T, van Dalen CJ, Senthilmohan R, Winn M, Venge P et al. Eosinophil peroxidase produces hypobromous acid in the airways of stable asthmatics. Free Radic Biol Med 2002;33:847-856.